Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Neurosci ; 7: 50, 2006 Jun 19.
Article in English | MEDLINE | ID: mdl-16784531

ABSTRACT

BACKGROUND: The LAR family Protein Tyrosine Phosphatase sigma (PTPsigma) has been implicated in neuroendocrine and neuronal development, and shows strong expression in specific regions within the CNS, including the subventricular zone (SVZ). We established neural stem cell cultures, grown as neurospheres, from the SVZ of PTPsigma knockout mice and sibling controls to determine if PTPsigma influences the generation and the phenotype of the neuronal, astrocyte and oligodendrocyte cell lineages. RESULTS: The neurospheres from the knockout mice acquired heterogeneous developmental characteristics and they showed similar morphological characteristics to the age matched siblings. Although Ptprs expression decreases as a function of developmental age in vivo, it remains high with the continual renewal and passage of the neurospheres. Stem cells, progenitors and differentiated neurons, astrocytes and oligodendrocytes all express the gene. While no apparent differences were observed in developing neurospheres or in the astrocytes and oligodendrocytes from the PTPsigma knockout mice, the neuronal migration patterns and neurites were altered when studied in culture. In particular, neurons migrated farther from the neurosphere centers and the neurite outgrowth exceeded the length of the neuronal processes from age matched sibling controls. CONCLUSION: Our results imply a specific role for PTPsigma in the neuronal lineage, particularly in the form of inhibitory influences on neurite outgrowth, and demonstrate a role for tyrosine phosphatases in neuronal stem cell differentiation.


Subject(s)
Neurons/physiology , Phenotype , Protein Tyrosine Phosphatases/physiology , Stem Cells/physiology , Animals , Cell Differentiation , Cell Movement , Isoenzymes/deficiency , Isoenzymes/physiology , Mice , Mice, Knockout , Neurites/physiology , Neurons/cytology , Neurons/enzymology , Protein Tyrosine Phosphatases/deficiency , Receptor-Like Protein Tyrosine Phosphatases, Class 2 , Spheroids, Cellular , Stem Cells/cytology , Stem Cells/enzymology
2.
J Neuroimmunol ; 169(1-2): 68-85, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16198428

ABSTRACT

Brain atrophy, neurologic and psychiatric (NP) manifestations are common complications in the systemic autoimmune disease, lupus erythematosus (SLE). Here we show that the cerebrospinal fluid (CSF) from autoimmune MRL-lpr mice and a deceased NP-SLE patient reduce the viability of brain cells which proliferate in vitro. This detrimental effect was accompanied by periventricular neurodegeneration in the brains of autoimmune mice and profound in vivo neurotoxicity when their CSF was administered to the CNS of a rat. Multiple ionic responses with microfluorometry and protein peaks on electropherograms suggest more than one mechanism of cellular demise. Similar to the CSF from diseased MRL-lpr mice, the CSF from a deceased SLE patient with a history of psychosis, memory impairment, and seizures, reduced viability of the C17.2 neural stem cell line. Proposed mechanisms of cytotoxicity involve binding of intrathecally synthesized IgG autoantibodies to target(s) common to different mammalian species and neuronal populations. More importantly, these results indicate that the viability of proliferative neural cells can be compromised in systemic autoimmune disease. Antibody-mediated lesions of germinal layers may impair the regenerative capacity of the brain in NP-SLE and possibly, brain development and function in some forms of CNS disorders in which autoimmune phenomena have been documented.


Subject(s)
Cerebrospinal Fluid/physiology , Lupus Erythematosus, Systemic/pathology , Neurons/physiology , Stem Cells/physiology , Age Factors , Analysis of Variance , Animals , Antigens, Nuclear/immunology , Autoantibodies/blood , Cardiolipins/immunology , Cell Count/methods , Cell Death/physiology , Cells, Cultured , Diagnostic Imaging/methods , Electrophoresis, Capillary/methods , Electrophoresis, Gel, Two-Dimensional/methods , Female , Fluoresceins , Glial Fibrillary Acidic Protein/metabolism , Humans , Intermediate Filament Proteins/metabolism , Lupus Erythematosus, Systemic/cerebrospinal fluid , Male , Mice , Mice, Inbred MRL lpr/cerebrospinal fluid , Middle Aged , Nerve Tissue Proteins/metabolism , Nestin , Neuroglia/metabolism , Organ Size/physiology , Organic Chemicals/metabolism , Rats , Time Factors
3.
Brain Res ; 1057(1-2): 105-12, 2005 Sep 28.
Article in English | MEDLINE | ID: mdl-16140285

ABSTRACT

Neural stem cell therapy has the potential to treat neurodegenerative disorders. For Parkinson's disease (PD), the goal is to enhance the dopamine system sufficiently to restore the control of movement and motor activities. In consideration of autologous stem cell therapy for PD, it will be necessary to propagate the cells in most cases from aged brain tissue. We isolated cells from the subventricular zone (SVZ) in the brains of 1-year-old enhanced green fluorescent protein (GFP) mice and generated neurospheres in culture. Neurospheres yielding high numbers of neurons and astrocytes "de novo" were selected and cryopreserved before evaluating the efficacy of neurosphere cell suspensions transplanted to the 6-hydroxydopamine (6-OHDA) model of PD. In mice unilaterally lesioned with 6-OHDA, transplants of neurosphere cell suspensions to the striatum yielded astrocytes and tyrosine hydroxylase positive neurons that reduced or reversed the drug-induced behavioral circling response to amphetamine and apomorphine. Control mice without the cell suspensions showed no change in the motor behavior. Our results indicate that the SVZ in the aged mouse brain contains cells that can be expanded in the form of neurospheres, cryopreserved, re-expanded and then transplanted into the damaged dopamine system to generate functional cell progeny that offset the motor disturbances in the nigrostriatal system.


Subject(s)
Aging/physiology , Neurons/physiology , Parkinson Disease/therapy , Stem Cell Transplantation/methods , Amphetamine/pharmacology , Animals , Apomorphine/pharmacology , Astrocytes/physiology , Behavior, Animal/drug effects , Behavior, Animal/physiology , Behavioral Symptoms/therapy , Corpus Striatum/cytology , Corpus Striatum/surgery , Disease Models, Animal , Dopamine Agonists/pharmacology , Dopamine Uptake Inhibitors/pharmacology , Functional Laterality , Glial Fibrillary Acidic Protein/metabolism , Green Fluorescent Proteins/biosynthesis , Green Fluorescent Proteins/genetics , Mice , Mice, Inbred C57BL , Mice, Transgenic , Neurofilament Proteins/metabolism , Oxidopamine/toxicity , Parkinson Disease/complications , Parkinson Disease/etiology , Time Factors , Tyrosine 3-Monooxygenase/metabolism
4.
BMC Neurosci ; 5: 41, 2004 Oct 28.
Article in English | MEDLINE | ID: mdl-15511288

ABSTRACT

BACKGROUND: In order to optimize the potential benefits of neural stem cell (NSC) transplantation for the treatment of neurodegenerative disorders, it is necessary to understand their biological characteristics. Although neurotrophin transduction strategies are promising, alternative approaches such as the modulation of intrinsic neurotrophin expression by NSCs, could also be beneficial. Therefore, utilizing the C17.2 neural stem cell line, we have examined the expression of selected neurotrophic factors under different in vitro conditions. In view of recent evidence suggesting a role for the pineal hormone melatonin in vertebrate development, it was also of interest to determine whether its G protein-coupled MT1 and MT2 receptors are expressed in NSCs. RESULTS: RT-PCR analysis revealed robust expression of glial cell-line derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in undifferentiated cells maintained for two days in culture. After one week, differentiating cells continued to exhibit high expression of BDNF and NGF, but GDNF expression was lower or absent, depending on the culture conditions utilized. Melatonin MT1 receptor mRNA was detected in NSCs maintained for two days in culture, but the MT2 receptor was not seen. An immature MT1 receptor of about 30 kDa was detected by western blotting in NSCs cultured for two days, whereas a mature receptor of about 40 - 45 kDa was present in cells maintained for longer periods. Immunocytochemical studies demonstrated that the MT1 receptor is expressed in both neural (beta-tubulin III positive) and glial (GFAP positive) progenitor cells. An examination of the effects of melatonin on neurotrophin expression revealed that low physiological concentrations of this hormone caused a significant induction of GDNF mRNA expression in NSCs following treatment for 24 hours. CONCLUSIONS: The phenotypic characteristics of C17.2 cells suggest that they are a heterogeneous population of NSCs including both neural and glial progenitors, as observed under the cell culture conditions used in this study. These NSCs have an intrinsic ability to express neurotrophic factors, with an apparent suppression of GDNF expression after several days in culture. The detection of melatonin receptors in neural stem/progenitor cells suggests involvement of this pleiotropic hormone in mammalian neurodevelopment. Moreover, the ability of melatonin to induce GDNF expression in C17.2 cells supports a functional role for the MT1 receptor expressed in these NSCs. In view of the potency of GDNF in promoting the survival of dopaminergic neurons, these novel findings have implications for the utilization of melatonin in neuroprotective strategies, especially in Parkinson's disease.


Subject(s)
Nerve Growth Factors/metabolism , Neurons/metabolism , Receptor, Melatonin, MT1/metabolism , Stem Cells/metabolism , Animals , Biomarkers/analysis , Cell Culture Techniques , Cell Line , Gene Expression , Glial Cell Line-Derived Neurotrophic Factor/biosynthesis , Glial Cell Line-Derived Neurotrophic Factor/genetics , Immunohistochemistry , Melatonin/pharmacology , Mice , Nerve Growth Factors/genetics , Neuroglia/chemistry , Neuroglia/cytology , Neuroglia/metabolism , Neurons/chemistry , Neurons/cytology , RNA, Messenger/metabolism , Receptor, Melatonin, MT1/analysis , Receptor, Melatonin, MT1/genetics , Receptor, Melatonin, MT2/analysis , Receptor, Melatonin, MT2/genetics , Receptor, Melatonin, MT2/metabolism , Stem Cells/chemistry , Stem Cells/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...